Jefferies Remains a Buy on Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Buy Now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,300.

​The rating is based on the company’s prescription data for GLP-1 medications. Oral Wegovy had roughly 89,300 IMS prescriptions and 76,800 Symphony prescriptions in the 10th week of its launch. The data outpace comparable launches of injectable Wegovy and Zepbound.

​On the other hand, data from other GLP-1 drugs witnessed declines, including Zepbound falling 3% to 17,100 prescriptions, Mounjaro dropping to 13,100 after a 2% decline, and injectable Wegovy decreased 3% to 9,710.

​The firm noted that the data for oral Wegovy is encouraging for Eli Lilly’s Orforglipron, ahead of its PDUFA date on April 10, 2026. The firm projects $2 billion in 2026 Orforglipron revenue, exceeding the $1.55 billion consensus, against Lilly’s guidance of $80 billion to $83 billion total revenue.

​Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

READ NEXT: 10 High-Flying Penny Stocks to Buy and 10 Cheap Stocks to Buy for High Returns in 2026. 

Disclosure: None. Follow Insider Monkey on Google News.